Numb and its alternative splicing in pancreatic cancer

Penghao LI; Kailian ZHENG; Xiongfei XU; Gang JIN

doi:10.3969/j.issn.1001-5256.2022.12.042

Volume 38 Issue 12

Dec. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(12): 2897-2900

PDF( 1884 KB)

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Department of Hepatobiliary Pancreatic and Splenic Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Research funding:

Natural Science Fund project of Shanghai 2020 "Science and Technology Innovation Action Plan" (20ZR1457300)

More Information

Corresponding author: ZHENG Kailian, zhengkl828@126.com (ORCID: 0000-0002-7341-0639)
Received Date: 2022-06-01
Accepted Date: 2022-07-22
Published Date: 2022-12-20

Abstract

Abstract

Pancreatic cancer, a common digestive system tumor with high malignancy and a poor prognosis, has several treatment options. However, none of them are particularly effective because understanding the pathogenesis of pancreatic cancer remains a significant clinical challenge. Splicing isoforms mediate various biological phenotypes as an important means of regulating gene expression in eukaryotes, and their abnormalities can lead to a variety of diseases. Numb is an important cell fate determining protein whose alternative splicing has been linked to the development of various cancers. In pancreatic cancer, selective splicing of Numb can result in a variety of Numb protein subtypes, each with a different regulatory effect on the activation of various cancer-related signal pathways and tumor cell biology. This paper reviews the recent progress of Numb protein research in pancreatic cancer, with a focus on the regulatory role of its different isoforms in pathogenesis.
- Pancreatic Neoplasms,
- Numb,
- Spliceosomes

FullText(HTML)

References(43)

References

[1]	MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/S0140-6736(20)30974-0.
[2]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. DOI: 10.3322/caac.21442.
[3]	GULINO A, DI MARCOTULLIO L, SCREPANTI I. The multiple functions of Numb[J]. Exp Cell Res, 2010, 316(6): 900-906. DOI: 10.1016/j.yexcr.2009.11.017.
[4]	WESTHOFF B, COLALUCA IN, D'ARIO G, et al. Alterations of the Notch pathway in lung cancer[J]. Proc Natl Acad Sci U S A, 2009, 106(52): 22293-22298. DOI: 10.1073/pnas.0907781106.
[5]	LU Y, XU W, JI J, et al. Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma[J]. Hepatology, 2015, 62(4): 1122-1131. DOI: 10.1002/hep.27923.
[6]	PECE S, SERRESI M, SANTOLINI E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis[J]. J Cell Biol, 2004, 167(2): 215-221. DOI: 10.1083/jcb.200406140.
[7]	ZHENG KL, HE TL, JI WP, et al. Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(6): 6181-6191.
[8]	SHENG W, DONG M, ZHOU J, et al. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer[J]. Cell Tissue Res, 2013, 354(2): 521-532. DOI: 10.1007/s00441-013-1679-6.
[9]	BECHARA EG, SEBESTYÉN E, BERNARDIS I, et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation[J]. Mol Cell, 2013, 52(5): 720-733. DOI: 10.1016/j.molcel.2013.11.010.
[10]	CHOI HY, SEOK J, KANG GH, et al. The role of NUMB/NUMB isoforms in cancer stem cells[J]. BMB Rep, 2021, 54(7): 335-343. DOI: 10.5483/BMBRep.
[11]	MCGILL MA, DHO SE, WEINMASTER G, et al. Numb regulates post-endocytic trafficking and degradation of Notch1[J]. J Biol Chem, 2009, 284(39): 26427-26438. DOI: 10.1074/jbc.M109.014845.
[12]	WANG C, NING K, HU HH, et al. Research progress in tumor microenvironment of pancreatic cancer[J]. Chin J Dig Surg, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018. 王超, 宁克, 胡欢欢, 等. 胰腺癌肿瘤微环境的研究进展[J]. 中华消化外科杂志, 2020, 19(1): 109-112. DOI: 10.3760/cma.j.issn.1673-9752.2020.01.018.
[13]	NATSUIZAKA M, WHELAN KA, KAGAWA S, et al. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma[J]. Nat Commun, 2017, 8(1): 1758. DOI: 10.1038/s41467-017-01500-9.
[14]	COUTURIER L, MAZOUNI K, SCHWEISGUTH F. Numb localizes at endosomes and controls the endosomal sorting of notch after asymmetric division in Drosophila[J]. Curr Biol, 2013, 23(7): 588-593. DOI: 10.1016/j.cub.2013.03.002.
[15]	COUTURIER L, MAZOUNI K, SCHWEISGUTH F. Inhibition of Notch recycling by Numb: relevance and mechanism(s)[J]. Cell Cycle, 2013, 12(11): 1647-1648. DOI: 10.4161/cc.24983.
[16]	FRISE E, KNOBLICH JA, YOUNGER-SHEPHERD S, et al. The Drosophila Numb protein inhibits signaling of the Notch receptor during cell-cell interaction in sensory organ lineage[J]. Proc Natl Acad Sci U S A, 1996, 93(21): 11925-11932. DOI: 10.1073/pnas.93.21.11925.
[17]	MCGILL MA, MCGLADE CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain[J]. J Biol Chem, 2003, 278(25): 23196-23203. DOI: 10.1074/jbc.M302827200.
[18]	MISQUITTA-ALI CM, CHENG E, O'HANLON D, et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer[J]. Mol Cell Biol, 2011, 31(1): 138-150. DOI: 10.1128/MCB.00709-10.
[19]	GVNGÖR C, HOFMANN BT, WOLTERS-EISFELD G, et al. Pancreatic cancer[J]. Br J Pharmacol, 2014, 171(4): 849-858. DOI: 10.1111/bph.12401.
[20]	BARMAN S, FATIMA I, SINGH AB, et al. Pancreatic cancer and therapy: Role and regulation of cancer stem cells[J]. Int J Mol Sci, 2021, 22(9): 4765. DOI: 10.3390/ijms22094765
[21]	TRUONG LH, PAUKLIN S. Pancreatic cancer microenvironment and cellular composition: Current understandings and therapeutic approaches[J]. Cancers (Basel), 2021, 13(19): 5028. DOI: 10.3390/cancers13195028.
[22]	YANG L, SHI P, ZHAO G, et al. Targeting cancer stem cell pathways for cancer therapy[J]. Signal Transduct Target Ther, 2020, 5(1): 8. DOI: 10.1038/s41392-020-0110-5.
[23]	NWAEBURU CC, ABUKIWAN A, ZHAO Z, et al. Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer[J]. Mol Cancer, 2017, 16(1): 23. DOI: 10.1186/s12943-017-0589-8.
[24]	LUU T. Epithelial-mesenchymal transition and its regulation mechanisms in pancreatic cancer[J]. Front Oncol, 2021, 11: 646399. DOI: 10.3389/fonc.2021.646399.
[25]	DONGRE A, WEINBERG RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2): 69-84. DOI: 10.1038/s41580-018-0080-4.
[26]	GAIANIGO N, MELISI D, CARBONE C. EMT and treatment resistance in pancreatic cancer[J]. Cancers (Basel), 2017, 9(9): 122. DOI: 10.3390/cancers9090122.
[27]	PAN G, LIU Y, SHANG L, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun (Lond), 2021, 41(3): 199-217. DOI: 10.1002/cac2.12138.
[28]	SHENG WW, DONG M, LIU ZR, et al. Relationship and clinicopathological significance of Numb and epithelial-mesenchymal transition related proteins in human pancreatic cancer[J]. Chin J Surg, 2016, 54(12): 929-934. DOI: 10.3760/cma.j.issn.0529-5815.2016.12.011. 盛伟伟, 董明, 刘峥嵘, 等. Numb与上皮细胞间质转分化相关蛋白在胰腺癌中表达的相关性及其临床病理学意义[J]. 中华外科杂志, 2016, 54(12): 929-934. DOI: 10.3760/cma.j.issn.0529-5815.2016.12.011.
[29]	SHENG W, TANG J, CAO R, et al. Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer[J]. Cell Death Dis, 2022, 13(2): 173. DOI: 10.1038/s41419-022-04609-y.
[30]	KRUSE JP, GU W. Modes of p53 regulation[J]. Cell, 2009, 137(4): 609-622. DOI: 10.1016/j.cell.2009.04.050.
[31]	HU J, CAO J, TOPATANA W, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies[J]. J Hematol Oncol, 2021, 14(1): 157. DOI: 10.1186/s13045-021-01169-0.
[32]	BYKOV V, ERIKSSON SE, BIANCHI J, et al. Targeting mutant p53 for efficient cancer therapy[J]. Nat Rev Cancer, 2018, 18(2): 89-102. DOI: 10.1038/nrc.2017.109.
[33]	TOSONI D, ZECCHINI S, COAZZOLI M, et al. The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells[J]. J Cell Biol, 2015, 211(4): 845-862. DOI: 10.1083/jcb.201505037.
[34]	CONFALONIERI S, COLALUCA IN, BASILE A, et al. Exon 3 of the NUMB gene emerged in the chordate lineage coopting the NUMB protein to the regulation of MDM2[J]. G3 (Bethesda), 2019, 9(10): 3359-3367. DOI: 10.1534/g3.119.400494.
[35]	COLALUCA IN, BASILE A, FREIBURGER L, et al. A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer[J]. J Cell Biol, 2018, 217(2): 745-762. DOI: 10.1083/jcb.201709092.
[36]	NEOPTOLEMOS JP, KLEEFF J, MICHL P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 333-348. DOI: 10.1038/s41575-018-0005-x.
[37]	ZHANG TP, LIU RZ, REN B. Current status and challenges of total neoadjuvant therapy for pancreatic cancer[J]. Chin J Dig Surg, 2022, 21(4): 461-464. DOI: 10.3760/cma.j.cn115610-20220320-00141. 张太平, 刘悦泽, 任博. 胰腺癌全程新辅助治疗的现状及挑战[J]. 中华消化外科杂志, 2022, 21(4): 461-464. DOI: 10.3760/cma.j.cn115610-20220320-00141.
[38]	HO WJ, JAFFEE EM, ZHENG L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540. DOI: 10.1038/s41571-020-0363-5.
[39]	ZENG S, PÖTTLER M, LAN B, et al. Chemoresistance in pancreatic cancer[J]. Int J Mol Sci, 2019, 20(18): 4504. DOI: 10.3390/ijms20184504.
[40]	HENG W, DONG M, CHEN C, et al. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer[J]. FASEB J, 2017, 31(6): 2429-2438. DOI: 10.1096/fj.201601240R.
[41]	SESHACHARYULU P, BAINE MJ, SOUCHEK JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868(1): 69-92. DOI: 10.1016/j.bbcan.2017.02.003.
[42]	RAJASEKAR P, O'NEILL CL, EELES L, et al. Epigenetic changes in endothelial progenitors as a possible cellular basis for glycemic memory in diabetic vascular complications[J]. J Diabetes Res, 2015, 2015: 436879. DOI: 10.1155/2015/436879.
[43]	ZHU D, XIA J, LIU C, et al. Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin[J]. Cell Signal, 2022, 93: 110268. DOI: 10.1016/j.cellsig.2022.110268.

Relative Articles

[1]	Shangyou ZHENG, Honghui JIANG, Chonghui HU, Tingting LI, Tianhao HUANG, Rihua HE, Yong JIANG, Rufu CHEN. Pancreatic cancer neuroecology： Current status， mechanisms， and prospect from multi-dimensional perspectives[J]. Journal of Clinical Hepatology, 2025, 41(4): 611-618. doi: 10.12449/JCH250403
[2]	Guodong SHI, Zipeng LU, Kuirong JIANG. Diagnosis and treatment of dyspepsia associated with pancreatic tumors[J]. Journal of Clinical Hepatology, 2023, 39(12): 2770-2774. doi: 10.3969/j.issn.1001-5256.2023.12.004
[3]	Yi YAN, Junmei JIA, Yarong GUO. Role of cancer-associated fibroblasts in drug resistance of pancreatic cancer[J]. Journal of Clinical Hepatology, 2022, 38(5): 1203-1208. doi: 10.3969/j.issn.1001-5256.2022.05.048
[4]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[5]	Jing WANG, Bin TAN, Zhijie ZHAO, Haochen ZHONG, Linlin QU. Genomic profile of pancreatic tumor in the coastal regions of Eastern China: A multicenter analysis of 40 cases[J]. Journal of Clinical Hepatology, 2022, 38(2): 409-414. doi: 10.3969/j.issn.1001-5256.2022.02.028
[6]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[7]	Yannan XU, Ping LIU, Yongping MU. Effects of different subtypes of Numb protein subtypes on liver fibrosis-related signaling pathways[J]. Journal of Clinical Hepatology, 2021, 37(1): 169-172. doi: 10.3969/j.issn.1001-5256.2021.01.036
[8]	Du Yan, Wang XiaoDong, Xin ZeChang, Mao FeiYu, Qian XiaoWei, Li DuGuang, Yao Jie. Experience in treatment of pancreatic body/tail tumor using distal pancreatectomy with celiac axis resection[J]. Journal of Clinical Hepatology, 2020, 36(5): 1112-1114. doi: 10.3969/j.issn.1001-5256.2020.05.032
[9]	Wang Kun, ABUDUREYIMU·Tuerhong, Yang Fan, Liu YaHui, Fu Yu, Zhang Wei. Endoscopic pancreatic stent placement combined with tumor enucleation for benign pancreatic neck tumor: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 185-186. doi: 10.3969/j.issn.1001-5256.2019.01.040
[10]	Xu Wen, Xu YanNan, Liu Ping, Mu YongPing. Role of the Numb gene in the progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1847-1850. doi: 10.3969/j.issn.1001-5256.2019.08.044
[11]	Zheng SuLi, Zhang TaiPing. An excerpt of laparoscopic surgery for pancreatic neoplasms: the European Association for Endoscopic Surgery clinical consensus conference（2017）[J]. Journal of Clinical Hepatology, 2017, 33(5): 816-819. doi: 10.3969/j.issn.1001-5256.2017.05.004
[12]	Zhang YongGuo, Guo XiaoZhong. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia: 2015 ASGE guidelines[J]. Journal of Clinical Hepatology, 2016, 32(4): 628-632. doi: 10.3969/j.issn.1001-5256.2016.04.003
[13]	Lu: Yan, Zhang XiaoWen. Classification and diagnosis of pancreatic cystic neoplasm[J]. Journal of Clinical Hepatology, 2016, 32(5): 968-971. doi: 10.3969/j.issn.1001-5256.2016.05.039
[14]	Li Zhao, Zhu JiYe. Treatment of pancreatic neuroendocrine tumor with liver metastases[J]. Journal of Clinical Hepatology, 2015, 31(5): 668-670. doi: 10.3969/j.issn.1001-5256.2015.05.007
[15]	Hou XiaoJia, Jin ZhenDong. Progress in additional new techniques of endoscopic ultrasound in treatment of pancreatic tumors[J]. Journal of Clinical Hepatology, 2015, 31(5): 671-673. doi: 10.3969/j.issn.1001-5256.2015.05.008
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic neuroendocrine neoplasms (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1246-1248. doi: 10.3969/j.issn.1001-5256.2014.12.004
[17]	Li XiaoQing, Qian JiaMing. Differentiation between gastrointestinal neuroendocrine tumors and pancreatic neuroendocrine tumors[J]. Journal of Clinical Hepatology, 2013, 29(7): 492-495. doi: 1001-5256 (2013) 07-0492-04
[18]	Chen Jie. Pathological and differential diagnoses of exocrine pancreatic tumors[J]. Journal of Clinical Hepatology, 2013, 29(1): 45-49.
[19]	Zhang WenYing, Jin ZhenDong. Endoscopic ultrasound -guided treatment for pancreatic tumor[J]. Journal of Clinical Hepatology, 2012, 28(8): 573-575+578.
[20]	Wang YaJun, Sun JiaBang. Experience in diagnosis and treatment of pancreatic cystic tumors[J]. Journal of Clinical Hepatology, 2010, 26(5): 472-475+489.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1509) PDF downloads(36)

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Numb and its alternative splicing in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.12.042

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content